"Undruggable" targets such as KRAS are particularly challenging in the development of drugs.We devised a novel chem. knockdown strategy, CANDDY (Chem. knockdown with Affinity aNd Degradation DYnamics) technol., which promotes protein degradation using small mols. (CANDDY mols.) that are conjugated to a degradation tag (CANDDY tag) modified from proteasome inhibitors.We demonstrated that CANDDY tags allowed for direct proteasomal target degradation independent of ubiquitination.We synthesized a KRAS-degrading CANDDY mol., TUS-007, which induced degradation in KRAS mutants (G12D and G12V) and wild-type KRAS.We confirmed the tumor suppression effect of TUS-007 in s.c. xenograft models of human colon cells (KRAS G12V) with i.p. administrations and in orthotopic xenograft models of human pancreatic cells (KRAS G12D) with oral administrations.Thus, CANDDY technol. has the potential to therapeutically target previously undruggable proteins, providing a simpler and more practical drug targeting approach and avoiding the difficulties in matchmaking between the E3 enzyme and the target.

Molecules

A First-Class Degrader Candidate Targeting Both KRAS G12D and G12V Mediated by CANDDY Technology Independent of Ubiquitination

Article

Author: Ishizaka, Masamichi ; Imanishi, Satoshi ; Iwasaki, Yoichi ; Itakura, Shoko ; Miyamoto-Sato, Etsuko ; Huang, Lijuan

“Undruggable” targets such as KRAS are particularly challenging in the development of drugs. We devised a novel chemical knockdown strategy, CANDDY (Chemical knockdown with Affinity aNd Degradation DYnamics) technology, which promotes protein degradation using small molecules (CANDDY molecules) that are conjugated to a degradation tag (CANDDY tag) modified from proteasome inhibitors. We demonstrated that CANDDY tags allowed for direct proteasomal target degradation independent of ubiquitination. We synthesized a KRAS-degrading CANDDY molecule, TUS-007, which induced degradation in KRAS mutants (G12D and G12V) and wild-type KRAS. We confirmed the tumor suppression effect of TUS-007 in subcutaneous xenograft models of human colon cells (KRAS G12V) with intraperitoneal administrations and in orthotopic xenograft models of human pancreatic cells (KRAS G12D) with oral administrations. Thus, CANDDY technology has the potential to therapeutically target previously undruggable proteins, providing a simpler and more practical drug targeting approach and avoiding the difficulties in matchmaking between the E3 enzyme and the target.

100 Deals associated with FuturedMe, Inc.

100 Translational Medicine associated with FuturedMe, Inc.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 17 Jul 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

FuturedMe, Inc.

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 17 Jul 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing